Skip to main content
SpringerLink
Log in

The Role of Angiotensin II Receptors in Stroke Protection

  • CARDIOVASCULAR RISK AND HYPERTENSION (PW DE LEEUW AND AH GRADMAN, SECTION EDITORS)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The hypothesis that angiotensin II (Ang II) might have a stroke-protective role was first proposed by Brown and Brown about 25 years ago. Their hypothesis was generated from the results of the first Medical Research Council trial in patients with mild to moderate hypertension, which showed that patients treated with the diuretic bendrofluazide had a 70% decrease in strokes compared with those treated with the β-blocker propranolol for similar blood pressure reduction. This hypothesis, which remained dormant for many years, was recently resurrected by several experimental studies that showed that the brain possesses its own renin-angiotensin system (RAS) similar to the one existing in the systemic circulation. These studies also showed that the brain RAS plays an important role in stroke prevention and neuronal protection through its active peptide Ang II. In addition, these studies demonstrated that the beneficial effects of Ang II are mediated through stimulation of its subtype 2 receptors, and possibly through stimulation of the subtype 4 receptors by Ang IV, a metabolite of Ang II. Drugs that selectively block the Ang II subtype 1 receptors, such as the angiotensin receptor blockers, have shown superior protection against strokes and neuronal damage than drugs that decrease the generation of Ang II, such as the angiotensin-converting enzyme inhibitors and β-blockers. In this review, the role of the Ang II receptors and their mechanism of action regarding stroke prevention are discussed in view of the evidence from experimental and clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brown MJ, Brown J. Does angiotensin II protect against strokes? Lancet. 1986;2:427–9.

    Article  PubMed  CAS  Google Scholar 

  2. The Medical Research Working Party. The MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97–104.

    Article  Google Scholar 

  3. Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens. 2007;9:454–9.

    Article  CAS  Google Scholar 

  4. Faure S, Bureau A, Oudart N, et al. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens. 2008;26:2008–15.

    Article  PubMed  CAS  Google Scholar 

  5. Fisher-Ferraro C, Nahmod VE, Goldstein DJ, Finkielman S. Angiotensin and rennin in the rat and dog brains. J Exp Med. 1971;133:353–61.

    Article  Google Scholar 

  6. Unger T, Badoer E, Ganten D, Lang RE, Retig R. Brain angiotensin: pathways and pharmacology. Circulation. 1988;77(Part 2):140–54.

    Google Scholar 

  7. Mergenthaler P, Dimagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis. 2004;19:151–67.

    Article  PubMed  CAS  Google Scholar 

  8. Astrup J, Siesjo BK, Symon L. Threshold in cerebral ischemia-the ischemic penumbra. Stroke. 1981;12:723–7.

    Article  PubMed  CAS  Google Scholar 

  9. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. The 2002 Thomas Willis lecture. Stroke. 2003;34:214–23.

    Article  PubMed  Google Scholar 

  10. Wilms H, Rosenstiel P, Deusscl G, Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs. 2005;5:245–53.

    Article  PubMed  CAS  Google Scholar 

  11. Chrysant SG. Vascular remodeling: the role of angiotensin converting enzyme inhibitors. Am Heart J. 1998;135:S21–30.

    Article  PubMed  CAS  Google Scholar 

  12. Vacher E, Richer C, Giudicelli JF. Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens. 1996;14:1341–8.

    Article  PubMed  CAS  Google Scholar 

  13. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT (1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;30:2391–8.

    Article  PubMed  CAS  Google Scholar 

  14. Engelhorn T, Goerike S, Doefler A, et al. The angiotensin II type 1 receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cerebral Blood Flow Metab. 2004;24:467–74.

    Article  Google Scholar 

  15. Brdon J, Kaiser S, Hageman F, et al. Comparison between early and delayed systemic treatment with candesartan of rats after ischemic stroke. J Hypertens. 2007;25:187–98.

    Article  PubMed  CAS  Google Scholar 

  16. Allen AM, Zhuo J, Mendelsohn FA. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol. 1999;10:S23–9.

    PubMed  CAS  Google Scholar 

  17. Millan MA, Jacobowitz DM, Aguillera C, Catt KJ. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA. 1991;88:11440–4.

    Article  PubMed  CAS  Google Scholar 

  18. Steckelings UM, Kaschina E, Unger T. The AT2 receptor—a matter of love and hate. Peptides. 2005;26:1401–9.

    Article  PubMed  CAS  Google Scholar 

  19. Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens. 2006;24:S115–21.

    Article  Google Scholar 

  20. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005;19:617–9.

    PubMed  CAS  Google Scholar 

  21. Wright JW, Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev. 1994;18:21–53.

    Article  PubMed  CAS  Google Scholar 

  22. Braszko J. The combination of the AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neurobiol Exp. 1996;56:49–54.

    CAS  Google Scholar 

  23. Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843–8.

    Article  PubMed  CAS  Google Scholar 

  24. Harding JW, Wright JW, Swanson GN, et al. AT4 receptors: specificity and distribution. Kidney Intern. 1994;46:1510–2.

    Article  CAS  Google Scholar 

  25. DeGasparo M, Catt KJ, Inagami T, et al. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72.

    CAS  Google Scholar 

  26. Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer’s disease. J Renin Angiotensin Aldosterone Syst. 2008;9:226–37.

    Article  PubMed  CAS  Google Scholar 

  27. Coleman JK, Krebs LT, Hamilton TA, et al. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV –induced renal cortical blood flow changes in rats. Peptides. 1998;19:269–77.

    Article  PubMed  CAS  Google Scholar 

  28. Hamilton TA, Handa RK, Harding JW, Wright JW. A role for the angiotensin IV/AT4 system in mediating natriuresis in the rat. Peptides. 2001;22:935–44.

    Article  PubMed  CAS  Google Scholar 

  29. Kramar EA, Harding JW, Wright JW. Angiotensin II-and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept. 1997;68:131–8.

    Article  PubMed  CAS  Google Scholar 

  30. Stragier B, Debundel D, Sarre S, et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev. 2008;13:321–37.

    Article  PubMed  CAS  Google Scholar 

  31. Fernandez LA, Caride VJ, Stromberg C, et al. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994;24:937–40.

    Article  PubMed  CAS  Google Scholar 

  32. Dalmay F, Mazouz H, Allard J, et al. Non- AT (1)- receptor mediated protective effect of angiotensin against acute ischemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst. 2001;2:103–6.

    PubMed  CAS  Google Scholar 

  33. Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther. 2008;326:773–82.

    Article  PubMed  CAS  Google Scholar 

  34. Dahlof B, Devereaux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in Losartan For Endpoint reduction (LIFE) in hypertension: a randomized trial against atenolol. Lancet. 2002;359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  35. Kjeldsen SE, Dahlof B, Devereaux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA. 2002;288:1491–8.

    Article  PubMed  CAS  Google Scholar 

  36. Lithell H, Hanson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.

    Article  PubMed  CAS  Google Scholar 

  37. Papademetriou V, Farsang C, Elmfeld D, et al. Stroke prevention with the angiotensin II type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175–80.

    PubMed  CAS  Google Scholar 

  38. Schrader J, Luders S, Kulshewski A, et al. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34:1699–703.

    Article  PubMed  Google Scholar 

  39. Schrader J, Luders S, Kulshewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a randomized controlled study (MOSES). Stroke. 2005;36:1218–26.

    Article  PubMed  CAS  Google Scholar 

  40. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with a regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–31.

    Article  PubMed  CAS  Google Scholar 

  41. Yusuf S, Koon KT, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The ONTARGET Investigators. N Engl J Med. 2008;358:1547–59.

    Article  PubMed  CAS  Google Scholar 

  42. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. The Telmisartan Randomised Assessment Study in ACE iN tolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Lancet. 2008;372:1174–83.

    Article  PubMed  CAS  Google Scholar 

  43. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. For the PRoFESS Study Group. N Engl J Med. 2008;359:1225–37.

    Article  PubMed  CAS  Google Scholar 

  44. Sandset EC, Barth PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomized, placebo-controlled, double-blind trial. Lancet. 2011;377:741–50.

    Article  PubMed  CAS  Google Scholar 

  45. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens. 2005;19:923–31.

    Article  PubMed  CAS  Google Scholar 

  46. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update. A report from the American Heart Association. Circulation. 2011;123:e18–e209.

    Article  PubMed  Google Scholar 

  47. Turnbull F, Neal B, Algert C, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–9.

    Article  PubMed  Google Scholar 

  48. Turnbull F, Neal B, Ninomiya T, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ. 2008;336:1121–7.

    Article  PubMed  CAS  Google Scholar 

  49. Czernichow S, Zanchetti A, Turnbull F, et al. Blood Pressure Lowering Treatment trialists’ Collaboration. The effects of blood pressure reduction and different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4–16.

    Article  PubMed  CAS  Google Scholar 

  50. Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527–35.

    Article  PubMed  CAS  Google Scholar 

  51. Turnbull F, Neal B, Pfeffer M, et al. Blood Pressure Treatment Trialists’ Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951–8.

    Article  PubMed  CAS  Google Scholar 

  52. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: a meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1665–83.

    Article  Google Scholar 

  53. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today. 2004;40:791–801.

    Article  PubMed  CAS  Google Scholar 

  54. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137–44.

    Article  PubMed  CAS  Google Scholar 

  55. Adams HP, Del Zoppo G, Albers MJ, et al. Guidelines for the early management of adults with ischemic stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007;38:1655–711.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University of Oklahoma College of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, OK, 73132, USA

    Steven G. Chrysant

Authors
  1. Steven G. Chrysant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven G. Chrysant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chrysant, S.G. The Role of Angiotensin II Receptors in Stroke Protection. Curr Hypertens Rep 14, 202–208 (2012). https://doi.org/10.1007/s11906-012-0257-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-012-0257-8

Keywords

Search

Navigation